TY - JOUR
T1 - A disintegrin and metalloprotease-17 and galectin-9 are important regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis
AU - Nielsen, Morten Aagaard
AU - Andersen, Thomas
AU - Etzerodt, Anders
AU - Kragstrup, Tue Wenzel
AU - Rasmussen, Tue Kruse
AU - Stengaard-Pedersen, Kristian
AU - Hetland, Merete Lund
AU - Hørslev-Petersen, Kim
AU - Junker, Peter
AU - Østergaard, Mikkel
AU - Hvid, Malene
AU - Moestrup, Søren K
AU - Deleuran, Bent
N1 - © The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: [email protected].
PY - 2016/10/1
Y1 - 2016/10/1
N2 - OBJECTIVE: Co-stimulatory T cell cytokines are important in the progression of RA. This study investigates the interplay between 4-1BB, a disintegrin and metalloprotease-17 (ADAM17) and galectin-9 (Gal-9) in RA.METHODS: Stimulated mononuclear cells from patients with chronic RA (n = 12) were co-incubated with tissue inhibitor of metalloproteinase, 4-1BB ligand and Gal-9. Plasma samples were examined for soluble 4-1BB (s4-1BB) in newly diagnosed, treatment-naïve patients with RA (n = 97). The 28-joint DAS with CRP (28DAS-CRP), total Sharp score, erosion score and joint space narrowing were used to evaluate treatment outcome serially over a 2-year period.RESULTS: RA CD4(+) and CD8(+) synovial T cells express high levels of 4-1BB. The addition of TNF-α to cultured synovial mononuclear cells increased shedding of 4-1BB. 4-1BB ligand only increased TNF-α shedding in combination with Gal-9. RNA interference-mediated knockdown of ADAM17 or the addition of an ADAM17 inhibitor reduced the 4-1BB shedding. Shedding of 4-1BB was not influenced by Gal-9. Plasma levels of s4-1BB were increased in early RA and correlated with the number of swollen joints at baseline. After 3 months of treatment, the plasma levels of s4-1BB were equal to those of the controls. Baseline plasma levels of s4-1BB were inversely correlated with DAS28-CRP after 2 years of treatment, but not with total Sharp score, erosion score or joint space narrowing.CONCLUSION: ADAM17 induces 4-1BB shedding in RA. Gal-9 is pivotal for the function of 4-1BB and induction of TNF-α. Furthermore, high plasma levels of s4-1BB were associated with the number of swollen joints, but also with a low DAS28-CRP after 2 years treatment in early RA.
AB - OBJECTIVE: Co-stimulatory T cell cytokines are important in the progression of RA. This study investigates the interplay between 4-1BB, a disintegrin and metalloprotease-17 (ADAM17) and galectin-9 (Gal-9) in RA.METHODS: Stimulated mononuclear cells from patients with chronic RA (n = 12) were co-incubated with tissue inhibitor of metalloproteinase, 4-1BB ligand and Gal-9. Plasma samples were examined for soluble 4-1BB (s4-1BB) in newly diagnosed, treatment-naïve patients with RA (n = 97). The 28-joint DAS with CRP (28DAS-CRP), total Sharp score, erosion score and joint space narrowing were used to evaluate treatment outcome serially over a 2-year period.RESULTS: RA CD4(+) and CD8(+) synovial T cells express high levels of 4-1BB. The addition of TNF-α to cultured synovial mononuclear cells increased shedding of 4-1BB. 4-1BB ligand only increased TNF-α shedding in combination with Gal-9. RNA interference-mediated knockdown of ADAM17 or the addition of an ADAM17 inhibitor reduced the 4-1BB shedding. Shedding of 4-1BB was not influenced by Gal-9. Plasma levels of s4-1BB were increased in early RA and correlated with the number of swollen joints at baseline. After 3 months of treatment, the plasma levels of s4-1BB were equal to those of the controls. Baseline plasma levels of s4-1BB were inversely correlated with DAS28-CRP after 2 years of treatment, but not with total Sharp score, erosion score or joint space narrowing.CONCLUSION: ADAM17 induces 4-1BB shedding in RA. Gal-9 is pivotal for the function of 4-1BB and induction of TNF-α. Furthermore, high plasma levels of s4-1BB were associated with the number of swollen joints, but also with a low DAS28-CRP after 2 years treatment in early RA.
KW - 4-1BB Ligand
KW - ADAM17 Protein
KW - Antirheumatic Agents
KW - Arthritis, Rheumatoid
KW - Autoantibodies
KW - CD8-Positive T-Lymphocytes
KW - Cells, Cultured
KW - Disease Progression
KW - Double-Blind Method
KW - Enzyme-Linked Immunosorbent Assay
KW - Galectins
KW - HEK293 Cells
KW - Humans
KW - Leukocytes, Mononuclear
KW - Longitudinal Studies
KW - Matrix Metalloproteinase 17
KW - Methotrexate
KW - Synovial Fluid
KW - T-Lymphocytes
KW - Tumor Necrosis Factor-alpha
KW - Journal Article
KW - Multicenter Study
KW - Randomized Controlled Trial
U2 - 10.1093/rheumatology/kew237
DO - 10.1093/rheumatology/kew237
M3 - Journal article
C2 - 27330157
SN - 1462-0324
VL - 55
SP - 1871
EP - 1879
JO - Rheumatology
JF - Rheumatology
IS - 10
ER -